Cipla, Novartis team up to make, market anti-diabetic drug
HQ Team April 10, 2023: Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 10, 2023: Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for.
HQ Team April 9, 2023: Suicides in Indiana, US, happens largely during the week of a full moon, between three and four in.
HQ Team April 8, 2023: Cancer vaccines will be ready by the end of this decade, according to pharmaceutical company Moderna’s chief medical.
HQ Team April 8, 2023: India’s federal government has told state authorities to identify emergency COVID-19 hotspots and ramp up testing, vaccination, and.
HQ Team April 7, 2023: The FDA has withdrawn Netherland-based Covis Pharma’s drug meant to cut preterm birth as it failed to prove.
H.Q. Team April 7, 2023: Dr. Reddy’s Laboratories, an Indian maker of generics and active pharmaceutical ingredients, has completed the acquisition of Mayne.
HQ Team April 5, 2023: Arbutus Biopharma Corporation and Genevant Sciences filed a lawsuit in a US court seeking compensation for Pfizer and BioNTech’s unlicensed use.
HQ Team April 5, 2023: Johnson and Johnson, a US multinational making pharmaceuticals and medical devices, has offered to pay $8.9 billion to.
HQ Team April 4, 2023: About one in six people worldwide suffer from infertility, a disease that disables the male or female reproductive.
HQ Team April 3, 2023: BioNTech SE and Duality Biologics (Suzhou) have signed a $1.5 billion deal to develop and commercialise two cancer.